A Phase 1 interventional study of clopidogrel and Placebo in Healthy, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-15.
Sponsored by Sanofi · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary objective:
Secondary Objectives:
The total study duration per subjects is 8-9 weeks broken down as follows:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy subject,
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: * Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions * Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily Period 2: * Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily * Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner * Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily
Drug: clopidogrel · Drug: omeprazole
Period 1: * Day 1: placebo loading dose in the morning under fasted conditions * Day 2 to Day 5: placebo in the morning under fasted conditions, once daily Period 2: * Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily * Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner * Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily
Drug: Placebo · Drug: omeprazole
Period 1: * Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily * Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner * Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily Period 2: * Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions * Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily
Drug: clopidogrel · Drug: omeprazole
Period 1: * Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner * Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner * Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily Period 2: * Day 1: placebo loading dose in the morning under fasted conditions * Day 2 to Day 5: placebo in the morning under fasted conditions, once daily
Drug: Placebo · Drug: omeprazole
Pharmaceutical form: tablet Route of administration: oral
Also known as: SR25990
Pharmaceutical form: matching tablet Route of administration: oral
Pharmaceutical form: delayed-release capsule Route of administration:oral
Maximum platelet aggregation intensity (MAI) induced by Adenosine diphosphate (ADP) 5µM after 5 days treatment
Time frame: Day 5 of each period
Maximum platelet aggregation intensity (MAI) induced by ADP 20µM after 5 days treatment
Time frame: Day 5 of each period
Platelet Reactivity Index - Vasodilatator-stimulated phosphoprotein test (PRI - VASP) after 5 days treatment
Time frame: Day 5 of each period
Clopidogrel pharmacokinetic parameters (maximum plasma concentration (Cmax) and area under the plasma concentration curve (AUC0-24)) after 5 days treatment
Time frame: Up to 24 hours postdose on Day 5 for each period
Clopidogrel active metabolite pharmacokinetic parameters (Cmax and AUC0-24) after 5 days treatment
Time frame: Up to 24 hours postdose on Day 5 for each period
The record gives a start of Mar 2009, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel